US Market News
3週前
PAVmed Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 15, 2026 8:00 AM
PR Newswire (US) Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submissionLucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestonesPAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoingConference call and webcast to be held today, May 15, at 8:30 AM EDTNEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the first quarter ended March 31, 2026. Conference Call and WebcastThe webcast will take place on Friday, May 15, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.Business Update Highlights"PAVmed now has a significantly simplified capital structure and strengthened balance sheet, positioning the Company to focus on execution across our core businesses and evaluate additional asset acquisition opportunities aligned with our long-term growth strategy," said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "Veris continues to expand its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission, and Lucid continues to build commercial momentum for EsoGuard with a strengthened balance sheet pending Medicare coverage. We are also actively advancing multiple technologies within our relaunched medical device portfolio under Joseph Virgilio's leadership, while increasingly leveraging his experience building and scaling growth-stage businesses."Highlights from the first quarter and recent weeks:Relaunched PAVmed medical device portfolio progressed multiple device opportunities under the leadership of Joseph Virgilio, including the PortIO implantable intraosseous vascular access device and endoscopic esophageal imaging technology licensed from Duke University. In addition to overseeing development and commercialization of the current and future device portfolio, Mr. Virgilio is also assuming broader responsibilities aligned with his experience building and scaling growth-stage medtech businesses.Veris continued development of its implantable physiological monitor, with presubmission and testing activities expected to begin soon in support of a planned FDA 510(k) submission.Veris further advanced its strategic engagement with The Ohio State University's James Cancer Hospital, with the commercial phase underway, expansion into additional departments in progress, and continued positive clinical and administrative feedback.Lucid Diagnostics announced first quarter 2026 financial results and key business developments, including:Recognized $1.3 million in EsoGuard® Esophageal DNA Test revenue for 1Q26 and processed 3,177 EsoGuard tests.Strengthened balance sheet with underwritten public offering of common stock, netting approximately $17?million in proceeds; ended 1Q26 with $45?million in proforma cash, extending runway into 2027.Strong presence at Digestive Disease Week (DDW), which included multiple EsoGuard abstracts, extensive engagement with the gastroenterology community, and a preview of a major upcoming clinical practice guideline update recommending EsoGuard and EsoCheck® as the only non-endoscopic test with high certainty of evidence.Financial Results:For the three months ended March 31, 2026, Operating expenses were approximately $8.1 million which include stock-based compensation expenses of $0.2 million. GAAP net loss attributable to common stockholders was approximately $7.0 million, or $(4.42) per common share on a diluted basis.As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted net loss was approximately $1.9 million or $(1.17) per common share.PAVmed had cash and cash equivalents of $6.5 million as of March 31, 2026, compared to $1.5 million as of December 31, 2025.The unaudited financial results for the three months ended March 31, 2026 were filed with the SEC on Form 10-Q on May 14, 2026, and are available at www.pavmed.com or www.sec.gov.PAVmed Non-GAAP MeasuresTo supplement our financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.Non-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three months ended March 31, 2026 and 2025 are as follows:
For the three months endedMarch 31,
2026
2025(in thousands except per-share amounts)
Revenue
$ 22
$ 8Operating expenses
8,057
5,454Other (Income) Expense, net
(6,971)
(24,069)Net (Income) Loss
1,064
(18,623)Net income (loss) per common share, diluted
$ (4.42)
$ 10.10Net income (loss) attributable to common stockholders
(6,988)
17,695Preferred Stock dividends and deemed dividends
6,928
1,273Net income (loss) as reported
(60)
18,968Adjustments:
Depreciation and amortization expense1
20
43Interest expense, net2
(16)
(4)NCI ownership share of Interest and Depreciation adjustments
(251)
—EBITDA
(307)
19,007
Other non-cash or financing related expenses:
Stock-based compensation expense3
182
930Operating expenses issued in stock1
1,951
50Change in FV equity method investments
(1,878)
(21,004)Change in FV convertible debt2
(3,260)
49Loss on debt extinguishment2
3,422
58Change in fair value – warrant liability
(1,831)
—Change in fair value – rights liability
(30)
—Non-GAAP adjusted net (loss)
$ (1,851)
$ (910)Non-GAAP shares outstanding, basic and diluted
1,581
463Non-GAAP adjusted net (loss) income per share, basic and diluted
$(1.17)
$(1.97)
1 Included in general and administrative expenses in the financial statements.
2 Included in other income and expenses.
3 Stock-based compensation ("SBC") expense is included in operating expenses and is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses: (in thousands except per-share amounts)
For the three months endedMarch 31,
2026
2025
Cost of revenue
$ 97
$ 36Stock-based compensation expense3
—
—Net cost of revenue
97
36
Sales and marketing
216
247Stock-based compensation expense3
(5)
(45)Net sales and marketing
211
202
General and administrative
6,356
4,384Depreciation expense
(20)
(43)Operating expenses issued in stock
(1,951)
(50)Stock-based compensation expense3
(155)
(796)Net general and administrative
4,230
3,495
Research and development
1,388
787Stock-based compensation expense3
(22)
(89)Net research and development
1,366
698
Total operating expenses
8,057
5,454Depreciation and amortization expense
(20)
(43)Operating expenses issued in stock
(1,951)
(50)Stock-based compensation expense3
(182)
(930)Net operating expenses
$ 5,904
$ 4,431About PAVmed and its SubsidiariesPAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.For more and for more information about PAVmed, please visit pavmed.com.For more information about Lucid Diagnostics, please visit luciddx.com.For more information about Veris Health, please visit verishealth.com. Forward-Looking StatementsThis press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-provides-business-update-and-reports-first-quarter-2026-financial-results-302773353.htmlSOURCE PAVmed Inc. Original: PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
US Market News
1月前
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common StockApril 24, 2026 10:23 AM
PR Newswire (US)
NEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $18 million. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners for the offering.The securities were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-291981) declared effective by the Securities and Exchange Commission on March 26, 2026. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC. Electronic copies of the final prospectus may be obtained on the SEC's website at http://www.sec.gov and may also be obtained from Canaccord Genuity LLC, Attn: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com or BTIG, LLC, 65 East 55th Street, New York, New York 10022, or by email at btig-ibd-equitycapitalmarkets@btig.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-closing-of-18-million-underwritten-offering-of-common-stock-302753005.htmlSOURCE Lucid Diagnostics
Original: Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
US Market News
1月前
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common StockApril 23, 2026 8:30 AM
PR Newswire (US)
NEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of an underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15M investment from a fundamental institutional investor with support from a large existing shareholder.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $18 million. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.The offering is expected to close on or about April 24, 2026, subject to customary closing conditions.Canaccord Genuity LLC and BTIG, LLC are acting as joint bookrunners for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-291981) declared effective by the Securities and Exchange Commission on March 26, 2026. The offering is being made only by means of a prospectus and a prospectus supplement which forms a part of the effective registration statement relating to the offering. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at http://www.sec.gov and may also be obtained, when available, by contacting Canaccord Genuity LLC, Attn: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com or BTIG, LLC, 65 East 55th Street, New York, New York 10022, or by email at btig-ibd-equitycapitalmarkets@btig.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock. Lucid will not, and has been advised by the underwriters that they and their affiliates will not, sell any of the shares of common stock in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-18-million-underwritten-offering-of-common-stock-302751719.htmlSOURCE Lucid Diagnostics
Original: Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
US Market News
2月前
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device PortfolioApril 2, 2026 8:01 AM
PR Newswire (US)
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's current and future medical device portfolio.
"Fixing PAVmed's capital structure and strengthening our balance sheet has allowed us to proceed with the long-anticipated relaunch our medical device portfolio under dedicated, experienced leadership," said PAVmed Chairman and Chief Executive Officer, Lishan Aklog, M.D. "We look forward to leveraging Mr. Virgilio's deep sector experience and leadership as we advance our existing medical device programs, while seeking to expand our pipeline with significant commercial opportunities which enhance long-term shareholder value. This relaunch is consistent with our mission to build a high-growth diversified commercial life sciences company with multiple independently financed subsidiaries operating under a shared services model."Medical Device LeadershipMr. Virgilio brings over 25 years of leadership experience across the medical device industry, with a track record of building and scaling medical technology businesses, advancing products from development through regulatory approval and commercialization, raising public and private capital, and establishing strategic partnerships.Mr. Virgilio most recently served as President and Chief Executive Officer of Morphic Medical, a clinical-stage company in the gastrointestinal and metabolic intervention space. He led the company's commercial and operational strategy, advanced key regulatory initiatives including EU approvals and a U.S. FDA pre-market authorization (PMA) study, during which time the company secured over $40 million in capital to support growth and execution.Mr. Virgilio has extensive prior experience building and scaling commercial organizations and driving adoption of innovative medical technologies at Amann Girrbach North America LP, Surgical Specialties Corporation (now Corza Medical Inc.), and Aptus Endosystems (acquired by Medtronic Inc.), as well as in earlier roles at Boston Scientific Inc. and Medtronic Inc. Mr. Virgilio has also served in industry-wide leadership roles on the Board of Directors of AdvaMed, the world's leading medical technology trade association, and its emerging company division, AdvaMed Accel."PAVmed has already established a strong foundation with its existing medical device programs, and I'm excited to build on that momentum," said Mr. Virgilio. "We have the opportunity to advance these assets while expanding the portfolio with additional high-quality opportunities. My focus will be on driving disciplined execution across the current portfolio, securing dedicated capital, advancing these programs toward key regulatory and commercial milestones, and continuing to build a diversified medical device portfolio through capital-efficient growth."Relaunched Medical Device PortfolioUnder Mr. Virgilio's leadership, PAVmed's has relaunched its medical device portfolio spanning assets across development and commercialization stages.The portfolio includes the Company's PortIO implantable intraosseous vascular access device, which is designed to enable rapid and reliable delivery of fluids, medications, and other therapeutics directly into the bone marrow cavity and central venous circulation.The portfolio also includes multi-modality endoscopic imaging technology recently licensed from Duke University, designed to identify and facilitate treatment of esophageal dysplasia during upper endoscopy. PAVmed and Duke University recently executed a definitive license agreement for this technology, following a previously announced letter of intent, through a newly formed PAVmed subsidiary, Octeris, Inc., Octeris will support ongoing sponsored research with Duke University to advance the development and clinical application of the technology.Mr Virgilio will serve as Chief Executive Officer of both subsidiaries—PortIO Inc. and Octeris Inc.PAVmed is actively pursuing additional medical device opportunities across various subsectors, with a focus on those with synergies to existing assets, including promising gastroesophageal reflux-focused technologies.About PAVmed and its SubsidiariesPAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.For more and for more information about PAVmed, please visit pavmed.com.For more information about Lucid Diagnostics, please visit luciddx.com.For more information about Veris Health, please visit verishealth.com. Forward-Looking StatementsThis press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-appoints-joseph-virgilio-to-lead-relaunched-medical-device-portfolio-302732458.htmlSOURCE PAVmed Inc.
Original: PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
US Market News
2月前
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 30, 2026 8:00 AM
PR Newswire (US)
PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submissionLucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM ESTNEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the fourth quarter and year ended December 31, 2025.
Conference Call and WebcastThe webcast will take place on Monday, March 30, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.Business Update Highlights"Over the past two years, we've undertaken a series of deliberate, systematic actions to fix PAVmed's legacy capital structure and strengthen its balance sheet," said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "This process is now complete and we believe PAVmed is exceptionally well positioned to execute on its founding mission — to operate as a high-growth diversified commercial life sciences company with multiple independently financed subsidiaries operating under a shared services model. Veris is now well underway in the commercial phase of its strategic engagement with OSU-The James while progressing its implantable physiological monitor toward FDA submission. Lucid continues to maintain a strong commercial foundation as it approaches transformative Medicare coverage for EsoGuard. We have also relaunched PAVmed's medical device portfolio under experienced leadership and completed the licensing of our endoscopic esophageal imaging technology from Duke University, adding another potential growth engine to our pipeline."Highlights from the fourth quarter and recent weeks:PAVmed strengthened its balance sheet through the completion of a $30 million Series D preferred stock offering and a $15 million senior secured note financing. A portion of the proceeds from these activities was used to eliminate all previously outstanding convertible securities, removing a significant legacy capital structure overhang and extending the Company's cash runway. In addition, the Company issued $30 million in Series D warrants, which are callable upon the publication of a draft CMS coverage policy for Lucid's EsoGuard Esophageal DNA Test.PAVmed relaunched its medical device portfolio and appointed industry veteran Joseph Virgilio as Chief Business Officer of Medical Devices to oversee development and commercialization of its current and future device portfolio, including the PortIO implantable intraosseous vascular access device and endoscopic esophageal imaging technology licensed from Duke University.Veris advanced its strategic engagement with The Ohio State University's James Cancer Hospital, with the commercial phase well underway and full integration with the hospital's electronic health record (EHR) system now complete.Veris is engaged with its development and manufacturing partner for its implantable physiological monitor, supporting a planned late 2026 FDA 510(k) submission.Lucid Diagnostics announced fourth quarter and full year 2025 financial results and key business developments, including:Recognized $1.5 million in EsoGuard® Esophageal DNA Test revenue for 4Q25 and processed 3,664 EsoGuard tests.Awarded U.S. Department of Veterans Affairs (VA) contract for EsoGuard, expanding access across the nation's largest integrated healthcare system serving approximately nine million veterans. Announced positive data from the largest reported real-world experience of esophageal precancer detection, evaluating Lucid's EsoGuard and EsoCheck® Esophageal Cell Collection Device in nearly 12,000 at-risk patients.Financial Results:For the three months ended December 31, 2025, Operating expenses were approximately $6.9 million which include stock-based compensation expenses of $0.3 million. GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per common share on a diluted basis.As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted loss was approximately $0.9 million or $(1.05) per common share.PAVmed had cash and cash equivalents of $1.5 million as of December 31, 2025, compared to $1.2 million as of December 31, 2024.The audited financial results for the year ended December 31, 2025 were filed with the SEC on Form 10-K on March 27, 2026, and are available at www.pavmed.com or www.sec.gov.PAVmed Non-GAAP MeasuresTo supplement our financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.Non-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three months and year ended December 31, 2025 and 2024 are as follows:Condensed Consolidated Statement of Operations (Unaudited)
For the three months endedDecember 31,
For the year endedDecember 31,
2025
2024
2025
2024(in thousands except per-share amounts)
Revenue
$ 52
$ 10
$ 71
$ 2,995Operating expenses
6,853
5 198
21,877
47,482Other (Income) Expense
(4,046)
(6 330)
(19,337)
(72,914)Net (Income) Loss
2,755
(1,142)
2,469
(28,427)Net income (loss) per common share, diluted
$ (2.05)
$ 3.60
$ (5.63)
$ 14.90Net income (loss) attributable to common stockholders
(1,832)
1,346
(3,774)
31,966Preferred Stock dividends and deemed dividends
569
85
4,175
7,825Net income (loss) as reported
(1,263)
1,431
401
39,791Adjustments:
Depreciation and amortization expense1
18
69
105
1,198Interest expense, net2
—
4
(8)
(209)NCI ownership share of Interest and Depreciation adjustments
(715)
—
(715)
(229)EBITDA
(1,960)
1,504
(217)
40,551
Other non-cash or financing related expenses:
Stock-based compensation expense3
232
733
1,707
6,449Operating expenses issued in stock1
350
150
505
598Gain on deconsolidation of subsidiary
—
—
—
(72,287)Change in FV equity method investments
(2,504)
(125)
(8,483)
(532)Change in FV convertible debt2
2,940
(2,950)
3,249
(462)Loss on debt extinguishment2
—
—
58
2,535Debt modification expense
—
—
—
2,000NCI ownership share of non-GAAP adjustments
—
—
—
(1,262)Non-GAAP adjusted (loss)
$ (942)
$ (688)
$ (3,141)
$ (22,410)Non-GAAP shares outstanding, basic and diluted
893
361
670
322Non-GAAP adjusted (loss) income per share, basic and diluted
$(1.05)
$(1.91)
$(4.69)
$(69.51)
1 Included in general and administrative expenses in the financial statements.
2 Included in other income and expenses.
3 Stock-based compensation ("SBC") expense is included in operating expenses and is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses: Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses(in thousands except per-share amounts)
For the three months endedDecember 31,
For the year endedDecember 31,
2025
2024
2025
2024
Cost of revenue
$ 86
$ 48
$ 218
$ 4,840Stock-based compensation expense3
—
—
—
(112)Net cost of revenue
86
48
218
4,728
Amortization of acquired intangible assets
—
—
—
559
Sales and marketing
249
155
917
11,627Stock-based compensation expense3
(2)
(18)
(61)
(1,100)Net sales and marketing
247
137
856
10,527
General and administrative
4,691
4,188
16,250
24,524Depreciation expense
(18)
(69)
(105)
(639)Operating expenses issued in stock
(350)
(150)
(505)
(598)Stock-based compensation expense3
(207)
(653)
(1,483)
(4,370)Net general and administrative
4,116
3,316
14,157
18,917
Research and development
1,827
807
4,492
5,932Stock-based compensation expense3
(23)
(62)
(163)
(867)Net research and development
1,804
745
4,329
5,065
Total operating expenses
6,853
5,198
21,877
47,482Depreciation and amortization expense
(18)
(69)
(105)
(1,198)Operating expenses issued in stock
(350)
(150)
(505)
(598)Stock-based compensation expense3
(232)
(733)
(1,707)
(6,449)Net operating expenses
$ 6,253
$ 4,246
$ 19,560
$ 39,237About PAVmed and its SubsidiariesPAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.For more and for more information about PAVmed, please visit pavmed.com.For more information about Lucid Diagnostics, please visit luciddx.com.For more information about Veris Health, please visit verishealth.com. Forward-Looking StatementsThis press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-302728534.htmlSOURCE PAVmed Inc.
Original: PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
US Market News
2月前
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 26, 2026 8:00 AM
PR Newswire (US)
Processed 3,664 EsoGuard® tests and recognized 4Q25 revenue of $1.5 millionExpanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detectionConference call and webcast to be held today, March 26, at 8:30 AM ESTNEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2025.
Conference Call and WebcastThe webcast will take place on Thursday, March 26, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.Business Highlights "Throughout 2025, we established a strong commercial foundation for EsoGuard, demonstrating that we can consistently generate and sustain demand, drive physician adoption, and engage effectively with both health systems and commercial payors," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "As we move into 2026, our focus is on building on that foundation by converting demand into revenue, with priorities including deepening our relationship with the VA, expanding adoption across health systems, advancing coverage with commercial payors, and securing Medicare coverage, which we still expect in the near-term."Highlights from the fourth quarter and recent weeks:Processed 3,664 EsoGuard® Esophageal DNA Tests in 4Q25.Recognized $1.5 million in EsoGuard revenue for 4Q25.Awarded U.S. Department of Veterans Affairs (VA) contract for EsoGuard, expanding access across the nation's largest integrated healthcare system serving approximately nine million veterans. The contract, issued under the VA Federal Supply Schedule, includes Medicare-aligned pricing of $1,938 and spans approximately 170 VA medical centers nationwide under a single national framework.Announced positive data from the largest reported real-world experience of esophageal precancer detection, evaluating Lucid's EsoGuard and EsoCheck® Esophageal Cell Collection Device in nearly 12,000 at-risk patients. Real-world data demonstrated that EsoCheck achieved a 95% technical success rate and that 95% of procedures were completed in under two minutes, while physicians used EsoGuard appropriately in routine clinical practice.Financial ResultsFor the three months ended December 31, 2025, EsoGuard related revenues were $1.5 million. Operating expenses were approximately $15.5 million, which included stock-based compensation expenses of $1.2 million. GAAP net loss attributable to common stockholders was approximately $16.3 million or $(0.12) per common share.As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted loss for the three months ended December 31, 2025 was approximately $12.6 million or $(0.10) per common share.Lucid had cash and cash equivalents of $34.7 million as of December 31, 2025, compared to $22.4 million as of December 31, 2024.The audited financial results for the year ended December 31, 2025, were filed with the SEC on Form 10-K on March 25, 2026, and available at www.luciddx.com or www.sec.gov.Lucid Non-GAAP MeasuresTo supplement our audited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense and other non-cash income and expenses, if any. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.
Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.
Non-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment, and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.
A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three months and years ended December 31, 2025, and 2024 are as follows:Condensed consolidated statements of operations (unaudited)(in thousands except per-share amounts)
For the three months endedDecember 31,
For the year endedDecember 31,
2025
2024
2025
2024
Revenue
$ 1,504
$ 1,197
$ 4,706
$ 4,346
Operating expenses
15,514
13,571
54,346
50,398Other (Income) expense
2,256
(833)
8,370
(523)Net Loss
(16,266)
(11,541)
(58,010)
(45,529)Net income (loss) per common share, basic and diluted
$ (0.12)
$ (0.20)
$ (0.69)
$ (1.05)Net loss attributable to common stockholders
(16,266)
(11,541)
(70,569)
(53,025)Preferred Stock dividends and deemed dividends
—
—
12,559
7,496Net income (loss) as reported
(16,266)
(11,541)
(58,010)
(45,529)Adjustments:
Depreciation and amortization expense1
210
222
872
1,167Interest expense, net2
(104)
(58)
(364)
(296)EBITDA
(16,160)
(11,377)
(57,502)
(44,658)
Other non-cash or financing related expenses:
Stock-based compensation expense3
1,165
1,172
4,491
4,534Operating expenses issued in stock1
—
98
234
346Change in FV convertible debt2
2,359
(4,825)
7,656
(5,394)Debt extinguishments loss - Senior Secured Convertible Note2
—
—
1,078
—Equity issuance cost extinguishment
—
4,050
—
5,167Non-GAAP adjusted (loss)
$ (12,636)
$ (10,882)
$ (44,043)
$ (40,005)Basic and Diluted shares outstanding
131,070
58,378
101,947
50,516Non-GAAP adjusted (loss) income per share
$(0.10)
$(0.19)
$(0.43)
$(0.79)
1 Included in general and administrative expenses in the financial statements.2 Included in other income and expenses.3 Stock-based compensation ("SBC") expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses: Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses(in thousands except per-share amounts)
For the three months endedDecember 31,
For the year endedDecember 31,
2025
2024
2025
2024Cost of revenues
$ 1,859
$ 2,145
$ 6,670
$ 7,099Stock-based compensation expense3
(39)
(42)
(191)
(164)Net cost of revenues
1,820
2,103
6,479
6,935
Amortization of intangible assets
106
105
421
688
Sales and marketing
5,343
4,003
17,710
16,463Stock-based compensation expense3
(269)
(300)
(1,021)
(1,365)Net sales and marketing
5,074
3,703
16,689
15,098
General and administrative
6,483
5,865
23,867
20,156Depreciation expense
(104)
(117)
(451)
(479)Operating expenses issued in stock
—
(98)
(234)
(346)Stock-based compensation expense3
(734)
(691)
(2,795)
(2,330)Net general and administrative
5,645
4,959
20,387
17,001
Research and development
1,723
1,453
5,678
5,992Stock-based compensation expense3
(123)
(139)
(484)
(675)Net research and development
1,600
1,314
5,194
5,317
Total operating expenses
15,514
13,571
54,346
50,398Depreciation and amortization expense
(210)
(222)
(872)
(1,167)Operating expenses issued in stock
—
(98)
(234)
(346)Stock-based compensation expense3
(1,165)
(1,172)
(4,491)
(4,534)Net operating expenses
$ 14,139
$ 12,079
$ 48,749
$ 44,351About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-302725817.htmlSOURCE Lucid Diagnostics
Original: Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Red Baron 1
4月前
glenn1919
4月前
georgie18
2年前
chemist72
2年前
Monksdream
2年前
ErnieBilco
4年前
メールアドレスで登録
